0001104659-23-081677.txt : 20230717 0001104659-23-081677.hdr.sgml : 20230717 20230717170440 ACCESSION NUMBER: 0001104659-23-081677 CONFORMED SUBMISSION TYPE: 3/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230713 FILED AS OF DATE: 20230717 DATE AS OF CHANGE: 20230717 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HENDERSON MICHAEL THOMAS CENTRAL INDEX KEY: 0001779990 FILING VALUES: FORM TYPE: 3/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-41740 FILM NUMBER: 231092262 MAIL ADDRESS: STREET 1: 421 KIPLING STREET CITY: PALO ALTO STATE: CA ZIP: 94301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Apogee Therapeutics, Inc. CENTRAL INDEX KEY: 0001974640 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 880588063 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 221 CRESCENT ST. STREET 2: BUILDING 17, SUITE 102B CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 650-394-5230 MAIL ADDRESS: STREET 1: 221 CRESCENT ST. STREET 2: BUILDING 17, SUITE 102B CITY: WALTHAM STATE: MA ZIP: 02453 FORMER COMPANY: FORMER CONFORMED NAME: Apogee Therapeutics, LLC DATE OF NAME CHANGE: 20230420 3/A 1 tm2321456-3_3aseq1.xml OWNERSHIP DOCUMENT X0206 3/A 2023-07-13 2023-07-13 0 0001974640 Apogee Therapeutics, Inc. APGE 0001779990 HENDERSON MICHAEL THOMAS C/O APOGEE THERAPEUTICS, INC. 221 CRESCENT ST., BLDG. 17, STE. 102B WALTHAM MA 02453 1 1 0 0 Chief Executive Officer Common Stock 1489487 D Includes (i) 851,495 shares of restricted common stock, which vest in 34 equal monthly installments through May 2, 2026, and (ii) 287,377 shares of restricted common stock, one quarter of which will vest on December 14, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, in each case subject to the Reporting Person's continued service to the Issuer. This amendment is being filed to correct the number of shares reported in Table I due to a calculation error. /s/ Jane Pritchett Henderson, as attorney-in-fact for Michael Henderson 2023-07-17